Metraipolis › archive › dc_63676bb2028e

Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies — Europe PMC PMID:42515723

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42515723
DOI
10.3390/ph19071041
License (as archived)
solo-consultazione
Archived
2026-10-18T11:29:15.849Z
SHA-256 of the archived text
9416784784df8619c46518439863d2b21d13af7e08630a86480ea561487218f2
Stable URL of this page
https://metraipolis.com/documento/dc_63676bb2028e

How to cite

Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies — Europe PMC PMID:42515723 — Europe PMC (en), https://europepmc.org/article/MED/42515723 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_63676bb2028e (Metraipolis archive dc_63676bb2028e, sha256 9416784784df8619c46518439863d2b21d13af7e08630a86480ea561487218f2)
BibTeX
@misc{dc63676bb2028e,
  title = {Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies — Europe PMC PMID:42515723},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42515723},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_63676bb2028e; sha256 9416784784df8619c46518439863d2b21d13af7e08630a86480ea561487218f2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42515723. Agents can read the archived copy with the MCP tool read_document.